Originally published by our sister publication Infectious Disease Special Edition
The benefits of vaccination with recombinant zoster vaccine (RZV; Shingrix, GSK) outweigh safety concerns in immunocompromised populations, according to a systematic review of studies involving multiple patient groups.
Patients who are immunocompromised, either due to their medical condition or immunosuppressive treatments, are at an elevated risk for herpes zoster. Bone marrow and stem cell